CIK 0002042347 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Seaport Therapeutics, Inc.
Sign in to watch- Ticker
- SPTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 992235719
- Phone
- 617-807-4062
- Business address
- 6 TIDE STREET, SUITE 400, BOSTON, MA, 02110
- Open-market buys, last 90 days
- $99,325
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$99,325. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Torres Denice Director | Purchase | +5,000 | $19.87 | $99K | 5,000 |
| 2026-06-22 | HOMBACH ROBERT J. Director | Purchase | +13,000 | $18.14 | $236K | 13,000 |
| 2026-05-04 | PureTech Health plc 10% owner | Conversion | +12,736,014 | 13,038,493 | ||
| 2026-05-04 | PureTech Health plc 10% owner | Conversion | +2,681,265 | 15,719,758 | ||
| 2026-05-04 | PureTech Health plc 10% owner | Conversion | +965,255 | 16,685,013 | ||
| 2026-05-04 | PureTech Health plc 10% owner | Conversion · Series A-1 Preferred Stock | −40,000,000 | 0 | ||
| 2026-05-04 | PureTech Health plc 10% owner | Conversion · Series A-2 Preferred Stock | −8,421,052 | 0 | ||
| 2026-05-04 | PureTech Health plc 10% owner | Conversion · Series B Preferred Stock | −3,031,578 | 0 | ||
| 2026-05-04 | HEALY JAMES Director | Conversion | +1,927,159 | 1,927,159 | ||
| 2026-05-04 | HEALY JAMES Director | Conversion | +804,379 | 2,731,538 | ||
| 2026-05-04 | HEALY JAMES Director | Conversion · Series A-2 Preferred Stock | −6,052,631 | 0 | ||
| 2026-05-04 | HEALY JAMES Director | Conversion · Series B Preferred Stock | −2,526,315 | 0 | ||
| 2026-05-04 | White Lauren Chief Financial Officer | Conversion | +6,702 | 6,702 | ||
| 2026-05-04 | White Lauren Chief Financial Officer | Conversion · Series B Preferred Stock | −21,052 | 0 | ||
| 2026-05-04 | Gladstein Lana General Counsel | Conversion | +33,515 | 33,515 | ||
| 2026-05-04 | Gladstein Lana General Counsel | Conversion · Series B Preferred Stock | −105,263 | 0 | ||
| 2026-05-04 | Chen Michael Cunyuan Chief Scientific Officer | Conversion | +3,351 | 3,351 | ||
| 2026-05-04 | Chen Michael Cunyuan Chief Scientific Officer | Conversion · Series B Preferred Stock | −10,526 | 0 | ||
| 2026-05-04 | Torres Denice Director | Conversion | +13,406 | 13,406 | ||
| 2026-05-04 | Torres Denice Director | Conversion · Series B Preferred Stock | −42,105 | 0 |
Page 1 of 3 · 42 trades